Our Recommendations
- Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV (2022)
- Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV (2020)
- Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men (2018)
- Consolidated guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection (2016)
- Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management (2018)
New Publications
- Preventing HIV misdiagnosis: implementation guide (2024)
- Dolutegravir Resistance in Malawi’s National HIV Treatment Program (2022)
- WFP Malawi Country Brief, April 2022 (2022)
- Malawi Country Operational Plan 2021 Strategic Direction Summary May 19, 2021 (2021)
- This 4 th Edition of the Malawi Guidelines for Clinical Management of HIV in Children and Adults will be implemented from July 2018 (2018)
Filter
346
Featured
Recommendations
13
New Publications
33
Language
Document type
No document type
121
Guidelines
116
Studies & Reports
62
Fact sheets
22
Infographics
9
Manuals
5
Situation Updates
3
Training Material
2
Resource Platforms
2
Strategic & Response Plan
2
Brochures
1
Online Courses
1
Countries / Regions
Malawi
8
Latin America and the Carribbean
7
South Africa
7
Global
6
Africa
5
East and Southern Africa
5
Uganda
4
Asia
3
South–East Asia Region
3
Western and Central Europe
3
Kenya
2
Lesotho
2
USA
2
Zambia
2
Nepal
1
El Salvador
1
Syria
1
Laos
1
Afghanistan
1
Zimbabwe
1
Philippines
1
Mozambique
1
Cambodia
1
Guinea-Bissau
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Western Pacific Region
1
North America
1
Jamaica
1
Bangladesh
1
Vietnam
1
Brazil
1
Sri Lanka
1
Russia
1
Yemen
1
Angola
1
Bhutan
1
India
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
53
Countries
29
Women & Child Health
7
Pharmacy & Technologies
3
Public Health
2
Capacity Building
1
Key Resources
1
Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...
Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi...
This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV programmes.
The latest data on safety and efficacy of do...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at red...
The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health response for 5 key populations (men who have sex with men, trans and gender diverse people, sex workers, people who inject drugs and people in prisons and...
This technical brief aims to support these trends, accelerated by the COVID-19 pandemic, and improve PrEP uptake, persistence, and effective use by providing implementation guidance for differentiated and simplified service delivery. The brief aims to support a range of stakeholders in planning and ...
An overview of validation structures and responsibilities at national, regional and global levels.
This governance document supplements the global guidance document. Validation of elimination requires rigorous assessment at the national, regional and global levels of the impact and process indicato...
Human Papilloma Virus (HPV) is the most common sexually transmitted infection, and two types of HPV (16 and 18) cause nearly 50% of high-grade cervical pre-cancers. HIV and cervical cancer are inextricably linked. Women living with HIV are six times more likely to develop cervical cancer, which is o...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...
The indicators and questions in this document are designed for use by national AIDS programmes and partners to assess the state of a country’s HIV and AIDS response, and to measure progress towards achieving national HIV targets. Countries are encouraged to integrate these indicators and questions...
All countries in the Latin American and Caribbean (LAC) region are expected to report on these indicators for the year 2022.
Despite progress in improving antiretroviral therapy (ART) for people with HIV in Malawi, the burden of HIV infections and HIV treatment outcomes among key populations is suboptimal. Client-centered differentiated service delivery approaches may facilitate addressing HIV prevention and treatment nee...
Malawi is a small landlocked country in Sub-Saharan Africa with a population expanding rapidly at 3 percent per year.
With most livelihoods dependent on rainfed agriculture, the population is highly vulnerable to the effects of natural disasters, prolonged dry spells and flash floods.
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 ...
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...
E-Learning for front-line managers on COVID-19 response to vulnerable populations (24 languages)
recommended
This e-learning course is designed for front-line managers of institutions hosting or serving people who are medially or socially vulnerable to the impact of COVID-19. It is a non-moderated and self-paced course. You can decide when to start it, interrupt and resume to continue at any time. In total...
25 February 2021
This technical guidance is a living document that builds on guidelines and reports of the UNAIDS Joint Programme. The definitions contained herein are working definitions that are subject to change. Updates will also be added further to the work of the multistakeholder Task Team on...
UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first editio...
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
This document is also available in Arabic and Portuguese.
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
